Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Boehringer Ingelheim
McKinsey
Merck
AstraZeneca

Last Updated: August 19, 2022

TWINJECT 0.3 Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Twinject 0.3, and when can generic versions of Twinject 0.3 launch?

Twinject 0.3 is a drug marketed by Impax and is included in one NDA. There are two patents protecting this drug.

This drug has forty-three patent family members in fifteen countries.

The generic ingredient in TWINJECT 0.3 is epinephrine. There are twenty-one drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Twinject 0.3

A generic version of TWINJECT 0.3 was approved as epinephrine by BELCHER on July 29th, 2014.

  Try it Free

US Patents and Regulatory Information for TWINJECT 0.3

TWINJECT 0.3 is protected by two US patents.

Patents protecting TWINJECT 0.3

Medicine injection devices and methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Method and apparatus for delivering epinephrine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax TWINJECT 0.3 epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-001 May 30, 2003 DISCN No No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Impax TWINJECT 0.3 epinephrine INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS 020800-001 May 30, 2003 DISCN No No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TWINJECT 0.3

See the table below for patents covering TWINJECT 0.3 around the world.

Country Patent Number Title Estimated Expiration
Spain 2173117 See Plans and Pricing
Russian Federation 2131748 AUTOMATIC OR MANUAL DEVICE FOR INJECTIONS OF LIQUID MEDICINAL AGENT See Plans and Pricing
World Intellectual Property Organization (WIPO) 9531235 See Plans and Pricing
European Patent Office 3263161 ENSEMBLE AIGUILLE D'INJECTION (INJECTION NEEDLE ASSEMBLY) See Plans and Pricing
South Africa 200704516 Medicine injection devices and methods See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Express Scripts
McKesson
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.